Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | FASN | P49327 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517873 | 1.00 | GSK3B (0.59) | GSK3BPTPN1CA12CA1CA2 | |
| SCHEMBL9409741 | 0.87 | GSK3B (0.70) | GSK3BPTPN1KDM4E | |
| Ethyl Acetate SCHEMBL31220759 | 0.84 | GSK3B (0.44) | GSK3BPTPN1CA12CA1CA2 | |
| SCHEMBL6259203 | 0.81 | CTNNB1 (0.55) | CA12CA1CA2CA6CA9 | |
| SCHEMBL108054 | 0.81 | CA12 (0.59) | CA12CA1CA2CA6CA9 | |
| SCHEMBL30497947 | 0.81 | CA12 (0.59) | CA12CA1CA2CA6CA9 | |
| SCHEMBL7392363 | 0.80 | L3MBTL1 (0.53) | CA12CA1CA2CA6CA9 | |
| SCHEMBL16787644 | 0.79 | GSK3B (0.59) | GSK3BPTPN1 | |
| SCHEMBL13305139 | 0.79 | CA12 (0.57) | CA12CA1CA2CA6CA9 | |
| SCHEMBL620024 | 0.79 | ALDH1A1 (0.59) | GSK3BCA12CA1CA2CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486739-A | Preparation method of impurities in phenylephrine hydrochloride bulk drug | 武汉武药制药有限公司 | 2024-02-02 | — | — | CN | claimed |
| US-20250257058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | US GOV VETERANS AFFAIRS (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-05-01 | — | — | US | disclosed |
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2025-03-11 | — | — | US | disclosed |
| CN-119192174-A | Novel biphenyl carboxylic FXR agonist, preparation method thereof and application thereof as medicine | 广东药科大学 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024161371-A1 | SUBSTITUTED AZOLES THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ALPHA-1 -ANTITRYPSIN (A1AT) DEFICIENCY | GT GAIN THERAPEUTICS SA (CH) | 2024-08-08 | — | — | WO | disclosed |
| EP-3802530-B1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN EV (DE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117486739-A | Preparation method of impurities in phenylephrine hydrochloride bulk drug | 武汉武药制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023101326-A1 | NOVEL COMPOUND AS AUTOTAXIN INHIBITOR AND USE THEREOF | 주식회사 넥스트젠바이오사이언스 | 2023-06-08 | — | — | WO | disclosed |
| US-4908386-A | Pharmaceuticals | GLAXO GROUP LIMITED (GB) | 1990-03-13 | — | — | US | disclosed |
| EP-0300074-A1 | Processes and intermediates useful in the preparation of Cis 1,3,4,6,7 llb-Hexa-hydro-7-aryl-2H-pyrazino[2,1-a]isoquinolines | PENNWALT CORPORATION (US) | 1989-01-25 | — | — | EP | disclosed |
| US-4772705-A | Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines | PENNWALT CORPORATION (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0220054-A2 | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
| EP-0063808-B1 | PHOTOGRAPHIC ELEMENTS CONTAINING NONDIFFUSIBLE 6-(2-THIENYLAZO)-3-PYRIDINOL CYAN DYE-RELEASING COMPOUNDS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-09-18 | — | — | EP | disclosed |
| US-4396546-A | Photographic products and processes employing novel nondiffusible 6-(2-thienylazo)-3-pyridinol cyan dye-releasing compounds and precursors thereof | EASTMAN KODAK COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4385104-A | METAL COORDINATION COMPLEX | EASTMAN KODAK COMPANY (US) | 1983-05-24 | — | — | US | disclosed |
| EP-0063808-A1 | Photographic elements containing nondiffusible 6-(2-thienylazo)-3-pyridinol cyan dye-releasing compounds | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1982-11-03 | — | — | EP | disclosed |
| US-4346161-A | DIFFUSION TRANSFER | EASTMAN KODAK COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| EP-0007205-A1 | Optically active phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | RXFP3, RXFP4, RXFP2 | GSK3B 3606/4885PTPN1 3956/4885CA12 2330/4885 |
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | PIK3CA, PIK3CD, PIK3C2B | GSK3B 331/4885PTPN1 523/4885CA12 4850/4885 |
| US-20250257058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | PELI1, MALT1, MCTS1 | GSK3B 3192/4885PTPN1 80/4885CA12 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.